• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

他克莫司软膏治疗眶周特应性皮炎

Tacrolimus Ointment in Periorbital Atopic Dermatitis.

作者信息

Alzahrani Mazen, Kamal Yumna F, Akram Muhammad A

机构信息

Ophthalmology, Jeddah Eye Hospital, Jeddah, SAU.

Medicine and Surgery, King Abdulaziz University, Jeddah, SAU.

出版信息

Cureus. 2024 Jan 27;16(1):e53055. doi: 10.7759/cureus.53055. eCollection 2024 Jan.

DOI:10.7759/cureus.53055
PMID:38410340
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10896248/
Abstract

Periorbital atopic dermatitis (AD) is a common sign in ophthalmological practice and usually has a persistent and relapsing course. Treatment with topical corticosteroids has various side effects associated with their usage. Tacrolimus topical ointment has unique immunomodulatory properties that decrease skin inflammation and pruritus in AD. In this case series, we present a prospective case series of five patients (three males and two females) who received topical application of tacrolimus ointment 0.1-0.03% in the periorbital area twice daily for one to four weeks. The pre- and post-treatment images of all patients were recorded to compare the effects of the treatment. The cases were selected from patients attending the outpatient clinics of East Jeddah Hospital, Saudi Arabia. All patients were suffering from AD. Patients underwent a clinical assessment by tactile inspection (location, size, color, and surface condition) in the first week, secondweek, third month, and first year. We may conclude from this study that tacrolimus showed promising outcomes and is safe and effective for the treatment of flares or resistant periorbital AD in both adults and children.

摘要

眶周特应性皮炎（AD）是眼科临床常见体征，通常呈持续性且易复发。外用糖皮质激素治疗存在多种与之相关的副作用。他克莫司软膏具有独特的免疫调节特性，可减轻AD患者的皮肤炎症和瘙痒。在本病例系列中，我们展示了一个前瞻性病例系列，共5例患者（3例男性，2例女性），他们在眶周区域每日两次外用0.1%-0.03%的他克莫司软膏，持续一至四周。记录所有患者治疗前后的图像以比较治疗效果。这些病例选自沙特阿拉伯吉达东部医院门诊的患者。所有患者均患有AD。患者在第一周、第二周、第三个月和第一年接受了通过触诊（部位、大小、颜色和表面状况）进行的临床评估。我们可以从这项研究得出结论，他克莫司对成人和儿童发作性或难治性眶周AD的治疗显示出良好的效果，且安全有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/0e7ad1222b2f/cureus-0016-00000053055-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/07a9f3b0a341/cureus-0016-00000053055-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/30a42ab2ca22/cureus-0016-00000053055-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/1833ee3dcb30/cureus-0016-00000053055-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/6ee8c16f3008/cureus-0016-00000053055-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/0e7ad1222b2f/cureus-0016-00000053055-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/07a9f3b0a341/cureus-0016-00000053055-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/30a42ab2ca22/cureus-0016-00000053055-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/1833ee3dcb30/cureus-0016-00000053055-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/6ee8c16f3008/cureus-0016-00000053055-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6f9d/10896248/0e7ad1222b2f/cureus-0016-00000053055-i05.jpg

相似文献

1
Tacrolimus Ointment in Periorbital Atopic Dermatitis.他克莫司软膏治疗眶周特应性皮炎
Cureus. 2024 Jan 27;16(1):e53055. doi: 10.7759/cureus.53055. eCollection 2024 Jan.
2
Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.外用他克莫司和外用糖皮质激素序贯应用治疗儿童特应性皮炎的疗效：一项开放标签的试点研究。
J Am Acad Dermatol. 2009 Feb;60(2):212-7. doi: 10.1016/j.jaad.2008.09.034. Epub 2008 Nov 22.
3
Topical tacrolimus for atopic dermatitis.外用他克莫司治疗特应性皮炎。
Cochrane Database Syst Rev. 2015 Jul 1;2015(7):CD009864. doi: 10.1002/14651858.CD009864.pub2.
4
Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.每周三次使用他克莫司软膏可减少稳定期特应性皮炎的复发：一种新的使用模式。
Pediatrics. 2008 Dec;122(6):e1210-8. doi: 10.1542/peds.2008-1343. Epub 2008 Nov 17.
5
Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan.0.1%他克莫司软膏与外用皮质类固醇激素治疗成人特应性皮炎的疗效及安全性比较：日本进行的随机双盲临床研究综述
Clin Drug Investig. 2006;26(5):235-46. doi: 10.2165/00044011-200626050-00001.
6
A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.一项针对中度至重度特应性皮炎成人患者使用0.1%他克莫司软膏进行长期治疗的多中心、随机、双盲、对照研究。
Br J Dermatol. 2005 Jun;152(6):1282-9. doi: 10.1111/j.1365-2133.2005.06592.x.
7
Safe and effective treatment of refractory facial lesions in atopic dermatitis using topical tacrolimus following corticosteroid discontinuation.停用皮质类固醇后使用外用他克莫司安全有效地治疗特应性皮炎中的难治性面部皮损。
Dermatology. 2001;203(1):32-7. doi: 10.1159/000051700.
8
Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.他克莫司软膏治疗中度至重度特应性皮炎患儿的疗效与安全性。
J Med Assoc Thai. 2006 Nov;89(11):1915-22.
9
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.每日一次 2%的克立硼罗软膏作为≥3 月龄轻中度特应性皮炎患者的长期维持治疗：一项 52 周的临床研究。
Am J Clin Dermatol. 2023 Jul;24(4):623-635. doi: 10.1007/s40257-023-00780-w. Epub 2023 May 15.
10
0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.对于中度至重度特应性皮炎儿童，每天涂抹一次或两次0.03%他克莫司软膏比1%醋酸氢化可的松更有效：一项随机双盲对照试验的结果。
Br J Dermatol. 2004 Mar;150(3):554-62. doi: 10.1046/j.1365-2133.2004.05782.x.

引用本文的文献

1
Adherence to Systemic Therapy for Atopic Dermatitis in Adult Patients in Saudi Arabia: A Cross-Sectional Study.沙特阿拉伯成年特应性皮炎患者对系统治疗的依从性：一项横断面研究。
Cureus. 2024 Nov 2;16(11):e72866. doi: 10.7759/cureus.72866. eCollection 2024 Nov.

本文引用的文献

1
Foundational concepts in the biology of bacterial keratitis.细菌性角膜炎生物学的基础概念。
Exp Eye Res. 2021 Aug;209:108647. doi: 10.1016/j.exer.2021.108647. Epub 2021 Jun 5.
2
Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.评估特应性皮炎与使用局部钙调磷酸酶抑制剂相关的癌症风险。
Br J Dermatol. 2011 Sep;165(3):465-73. doi: 10.1111/j.1365-2133.2011.10363.x. Epub 2011 Jun 30.
3
Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis--case series.0.03%他克莫司局部单药治疗春季角结膜炎——病例系列
Br J Ophthalmol. 2010 Oct;94(10):1405-6. doi: 10.1136/bjo.2009.172387. Epub 2010 Jun 16.
4
Periorbital contact sensitization.眶周接触致敏。
Am J Ophthalmol. 2010 Sep;150(3):366-370.e2. doi: 10.1016/j.ajo.2010.03.026. Epub 2010 Jun 11.
5
A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis.一项随机、安慰剂对照的临床试验，研究他克莫司滴眼液 0.1%在严重过敏性结膜炎中的应用。
J Ocul Pharmacol Ther. 2010 Apr;26(2):165-74. doi: 10.1089/jop.2009.0087.
6
Association between exposure to topical tacrolimus or pimecrolimus and cancers.局部使用他克莫司或吡美莫司与癌症的关联性。
Ann Pharmacother. 2009 Dec;43(12):1956-63. doi: 10.1345/aph.1M278. Epub 2009 Nov 10.
7
A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.一项针对头颈部特应性皮炎且对局部皮质类固醇不耐受或依赖的青少年和成年人的1%吡美莫司乳膏随机对照试验。
Br J Dermatol. 2007 Nov;157(5):954-9. doi: 10.1111/j.1365-2133.2007.08192.x.
8
The aetiology of eyelid dermatitis: a 10-year retrospective analysis.眼睑皮炎的病因：一项10年回顾性分析。
Contact Dermatitis. 2006 Nov;55(5):280-5. doi: 10.1111/j.1600-0536.2006.00927.x.
9
Atopic dermatitis management with tacrolimus ointment (Protopic).他克莫司软膏（普特彼）治疗特应性皮炎
J Dermatolog Treat. 2003;14(Suppl 1):5-16.
10
Topical tacrolimus treatment of atopic eyelid disease.
Am J Ophthalmol. 2003 Mar;135(3):297-302. doi: 10.1016/s0002-9394(02)01982-7.